Vir Biotechnology has expanded its board from eight members to nine, appointing Suzanne Topalian, M.D., as a director. She also joins the board’s Science and Technology Committee.
The appointment took effect October 27, 2026. Topalian will serve as a Class III director through the company’s 2028 annual meeting.
Key details
- Topalian fills a newly created board seat; the company said her appointment was not made under an arrangement with another person.
- She will receive the standard cash and equity compensation provided to non-employee directors. Under the company’s director compensation policy, she received stock options and restricted stock units when she joined; the announcement did not specify the award amounts.
- The company also entered into its standard indemnification agreement with Topalian, in addition to the protections for directors in its bylaws.
What changes
The board now has one additional member, and Topalian will have a role on the committee overseeing science and technology matters. The announcement does not describe any other changes to the company’s governance or strategy.